PEOPLE - UK private equity and venture capital firm 3I makes appointment:
This article was originally published in Clinica
Executive Summary
As part of its aim to increase its investment in healthcare, London-based UK private equity and venture capital firm 3i has appointed Peter Chambre as an industrialist-in-residence. Mr Chambre has 13 years' experience of leading healthcare companies, including Bespak (CEO), the Cambridge Antibody Technology Group (CEO) and Celera Genomics Group (COO). As part of 3i's industrialist-in-residence programme, Mr Chambre will identify, evaluate and complete deals in the healthcare sector, and provide significant levels of leadership assistance to businesses that are backed by 3i. Mr Chambre is currently a non-executive director of BTG (life sciences, UK) and Spectris (precision engineering, UK).
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.